At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 92 enrolled
Drug / intervention
PRCL-02 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2a Study to Evaluate Safety, Tolerability, and Efficacy of PRCL-02 in Patients With Moderate to Severe Chronic Plaque Psoriasis
In Brief
A Phase 2 clinical trial evaluating PRCL-02 and Placebo for Psoriasis Vulgaris and Plaque Psoriasis. Completed, enrolled 92 participants across 16 sites in 3 countries.
Detailed Summary
The aim of this study is to evaluate safety, tolerability, and efficacy of PRCL-02 in moderate to severe chronic plaque psoriasis
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis Vulgaris, Plaque Psoriasis
CountriesCanada, Slovakia, Ukraine
Collaborators--
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedAug 2018
Enrollment StartSep 2018
Primary CompletionApr 2019
Study CompletionJul 2019
TodayJul 2026
First PostedAug 3, 2018
Enrollment StartSep 25, 2018
Primary CompletionApr 29, 2019
Study CompletionJul 8, 2019
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 7.9 years ago
Interventions
PRCL-02drug
Oral tablets
Placebodrug
Oral tablets